AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads

NEW YORK–(BUSINESS WIRE)–AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.

“Guilin and Amy are exceptional leaders joining AnHeart at an exciting time for the company. In the last month, we shared positive data from our global pivotal TRUST-II trial for taletrectinib, which has the potential to be a best-in-class therapy for people with ROS1-positive non-small cell lung cancer,” said Jerry Wang, PhD, Chief Executive Officer. “Their respective expertise will enable us to advance our oncology pipeline and bring us a step closer towards our ultimate goal of bringing precision therapies to people with cancer in need of better options.”

Guilin Huang, Senior Vice President, Development

Guilin joins AnHeart with more than 20 years of global drug development experience in oncology and rare disease. Guilin has joined AnHeart’s executive leadership team and will lead development strategy for the company’s pipeline with a near-term focus on its lead investigational precision therapy, taletrectinib, as AnHeart continues to make progress towards commercialization.

Prior to AnHeart, Guilin served as Vice President, Head of Regulatory Affairs at Relay Therapeutics where she built and led the regulatory affairs function and played a critical role in advancing the development of multiple oncology programs. She previously served as Senior Director, Regulatory Strategy and Lung Cancer Franchise Lead at Takeda and Director, Regulatory Affairs at ARIAD Pharmaceuticals. Guilin has been instrumental in the global development of several breakthrough therapies, and her development experience ranges from pre-investigational new drug activities through registrations and post-registration.

Amy Muse, Vice President, U.S. Commercial

Amy joins AnHeart with more than 20 years of commercial experience in the pharmaceutical and biotech industry. Amy will lead commercial strategy for AnHeart’s investigational precision therapies in the United States, focusing initially on preparing AnHeart for the commercial launch of taletrectinib.

Prior to AnHeart, Amy served as Vice President, Marketing at Seres Therapeutics where she led the launch of the first FDA-approved oral microbiome therapeutic. Previously, she served as the U.S. Oncology Lung Cancer Franchise Lead at Takeda where she led commercial efforts for Takeda’s precision therapies for EGFR-positive and ALK-positive non-small cell lung cancer in the United States. Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.

About AnHeart Therapeutics

AnHeart Therapeutics (“AnHeart”) is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. Our lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration and the China National Medical Products Administration. AnHeart’s second investigational therapy, safusidenib, is a mIDH1-inhibitor being evaluated in a Phase 2 trial for IDH1-mutant glioma.

Our mission is to improve the lives of people with cancer. We are supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and Shanghai. For more information, visit https://www.anhearttherapeutics.com/ or follow us on LinkedIn at https://www.linkedin.com/company/anheart-therapeutics-official/.

Contacts

Charlotte Arnold, Chief Corporate Affairs Officer

Investors: [email protected]
Media: [email protected]